Drugmaker Regeneron Pharmaceuticals says it will comply with privacy policies regarding the use of customer data. 23andMe’s bankruptcy filings had drawn scrutiny from lawmakers who warned that millions of customers’ genetic data could be sold to unscrupulous buyers.